Nonsteroidal anti-inflammatory drugs do not interfere with imiquimod treatment for usual type vulvar intraepithelial neoplasia

International Journal of Cancer

Volumn 128, Issue 10, 2011, Pages 2463-2469

  Terlou, Annelinde ^a   Kleinjan, Alex ^a   Beckmann, Ilse ^a   Heijmans Antonissen, Claudia ^a   Van Seters, Manon ^a   Santegoets, Lindy A M ^a   Van Beurden, Marc ^b   Helmerhorst, Theo J M ^a   Blok, Leen J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

human papilloma virus; imiquimod; nonsteroidal anti inflammatory drugs; vulvar intraepithelial neoplasia

Indexed keywords

ACETYLSALICYLIC ACID; B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; HLA DR ANTIGEN; IBUPROFEN; IMIQUIMOD; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; IN VITRO STUDY; LANGERHANS CELL; LOW DRUG DOSE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MONOCYTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; TREATMENT RESPONSE; VAGINAL INTRAEPITHELIAL NEOPLASIA;

AMINOQUINOLINES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; BIOPSY; CARCINOMA IN SITU; CELL SEPARATION; DRUG INTERACTIONS; FEMALE; FLOW CYTOMETRY; FLUORESCENT DYES; HUMANS; IMMUNOHISTOCHEMISTRY; VULVAR NEOPLASMS;

EID: 79953178254     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25573     Document Type: Article

References (35)

1. Sideri M, Jones RW, Wilkinson EJ, Preti M, Heller DS, Scurry J, Haefner H, Neill S,. Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. J Reprod Med 2005; 50: 807-10. (Pubitemid 41720964)
2. Giuliano AR, Tortolero-Luna G, Ferrer E, Burchell AN, de Sanjose S, Kjaer SK, Munoz N, Schiffman M, Bosch FX,. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 2008; 26 (Suppl 10): K17-28.
3. Goffin F, Mayrand MH, Gauthier P, Alobaid A, Lussier C, Provencher D, Drouin P, Franco EL, Coutlee F,. High-risk human papillomavirus infection of the genital tract of women with a previous history or current high-grade vulvar intraepithelial neoplasia. J Med Virol 2006; 78: 814-9.
4. Heard I, Tassie JM, Schmitz V, Mandelbrot L, Kazatchkine MD, Orth G,. Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high human papillomavirus load(1). Obstet Gynecol 2000; 96: 403-9.
5. Jamieson DJ, Paramsothy P, Cu-Uvin S, Duerr A, Group HIVERS,. Vulvar, vaginal, and perianal intraepithelial neoplasia in women with or at risk for human immunodeficiency virus. Obstet Gynecol 2006; 107: 1023-8.
6. Khan AM, Freeman-Wang T, Pisal N, Singer A,. Smoking and multicentric vulval intraepithelial neoplasia. J Obstet Gynaecol 2009; 29: 123-5.
7. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM,. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370: 59-67. (Pubitemid 47017468)
8. Schiller M, Metze D, Luger TA, Grabbe S, Gunzer M,. Immune response modifiers-mode of action. Exp Dermatol 2006; 15: 331-41.
9. Schon MP, Schon M,. Imiquimod: mode of action. Br J Dermatol 2007; 157 (Suppl 2): 8-13. (Pubitemid 350179622)
10. van Seters M, van Beurden M, ten Kate FJ, Beckmann I, Ewing PC, Eijkemans MJ, Kagie MJ, Meijer CJ, Aaronson NK, Kleinjan A, Heijmans-Antonissen C, Zijlstra FJ, et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med 2008; 358: 1465-73. (Pubitemid 351482738)
11. Iavazzo C, Pitsouni E, Athanasiou S, Falagas ME,. Imiquimod for treatment of vulvar and vaginal intraepithelial neoplasia. Int J Gynaecol Obstet 2008; 101: 3-10.
12. Vane JR,. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232-5.
13. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB,. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004; 23: 9247-58. (Pubitemid 40069695)
14. Yin MJ, Yamamoto Y, Gaynor RB,. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998; 396: 77-80. (Pubitemid 28520452)
15. Amann R, Peskar BA,. Anti-inflammatory effects of aspirin and sodium salicylate. Eur J Pharmacol 2002; 447: 1-9. (Pubitemid 34775215)
16. Tegeder I, Pfeilschifter J, Geisslinger G,. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. Faseb J 2001; 15: 2057-72. (Pubitemid 32927924)
17. Scheuren N, Bang H, Munster T, Brune K, Pahl A,. Modulation of transcription factor NF-kappaB by enantiomers of the nonsteroidal drug ibuprofen. Br J Pharmacol 1998; 123: 645-52. (Pubitemid 128515013)
18. Hackstein H, Morelli AE, Larregina AT, Ganster RW, Papworth GD, Logar AJ, Watkins SC, Falo LD, Thomson AW,. Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells. J Immunol 2001; 166: 7053-62. (Pubitemid 32525574)
19. Matasic R, Dietz AB, Vuk-Pavlovic S,. Cyclooxygenase-independent inhibition of dendritic cell maturation by aspirin. Immunology 2000; 101: 53-60.
20. Geissmann F, Prost C, Monnet JP, Dy M, Brousse N, Hermine O,. Transforming growth factor beta1, in the presence of granulocyte/macrophage colony-stimulating factor and interleukin 4, induces differentiation of human peripheral blood monocytes into dendritic Langerhans cells. J Exp Med 1998; 187: 961-6. (Pubitemid 28141669)
21. Larregina AT, Morelli AE, Spencer LA, Logar AJ, Watkins SC, Thomson AW, Falo LD Jr., Dermal-resident CD14+ cells differentiate into Langerhans cells. Nat Immunol 2001; 2: 1151-8. (Pubitemid 33130150)
22. van Seters M, Beckmann I, Heijmans-Antonissen C, van Beurden M, Ewing PC, Zijlstra FJ, Helmerhorst TJ, KleinJan A,. Disturbed patterns of immunocompetent cells in usual-type vulvar intraepithelial neoplasia. Cancer Res 2008; 68: 6617-22.
23. Schuurhuis DH, Fu N, Ossendorp F, Melief CJ,. Ins and outs of dendritic cells. Int Arch Allergy Immunol 2006; 140: 53-72.
24. Merad M, Ginhoux F, Collin M,. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat Rev Immunol 2008; 8: 935-47.
25. Harizi H, Gualde N,. The impact of eicosanoids on the crosstalk between innate and adaptive immunity: the key roles of dendritic cells. Tissue Antigens 2005; 65: 507-14. (Pubitemid 40776298)
26. Legler DF, Krause P, Scandella E, Singer E, Groettrup M,. Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. J Immunol 2006; 176: 966-73. (Pubitemid 43099695)
27. Scandella E, Men Y, Legler DF, Gillessen S, Prikler L, Ludewig B, Groettrup M,. CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2. Blood 2004; 103: 1595-601. (Pubitemid 38268947)
28. Krause P, Bruckner M, Uermosi C, Singer E, Groettrup M, Legler DF,. Prostaglandin E(2) enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells. Blood 2009; 113: 2451-60.
29. Rescigno M, Martino M, Sutherland CL, Gold MR, Ricciardi-Castagnoli P,. Dendritic cell survival and maturation are regulated by different signaling pathways. J Exp Med 1998; 188: 2175-80. (Pubitemid 28562533)
30. Buckland M, Jago C, Fazekesova H, George A, Lechler R, Lombardi G,. Aspirin modified dendritic cells are potent inducers of allo-specific regulatory T-cells. Int Immunopharmacol 2006; 6: 1895-901.
31. Whittaker DS, Bahjat KS, Moldawer LL, Clare-Salzler MJ,. Autoregulation of human monocyte-derived dendritic cell maturation and IL-12 production by cyclooxygenase-2-mediated prostanoid production. J Immunol 2000; 165: 4298-304.
32. Oliveira BL, Cavalcanti CM, Azevedo AP, Tomiyoshi MY, Bergami-Santos PC, Barbuto JA,. Human monocytes but not dendritic cells are killed by blocking of autocrine cyclooxygenase activity. Cell Immunol 2009; 258: 107-14.
33. Hartel C, von Puttkamer J, Gallner F, Strunk T, Schultz C,. Dose-dependent immunomodulatory effects of acetylsalicylic acid and indomethacin in human whole blood: potential role of cyclooxygenase-2 inhibition. Scand J Immunol 2004; 60: 412-20. (Pubitemid 39331497)
34. Harizi H, Juzan M, Pitard V, Moreau JF, Gualde N,. Cyclooxygenase-2- issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J Immunol 2002; 168: 2255-63. (Pubitemid 34171825)
35. Davies NM,. Clinical pharmacokinetics of ibuprofen. The first 30 years. Clin Pharmacokinet 1998; 34: 101-54. (Pubitemid 28077672)